Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell, Marginal Zone 3Waldenstrom Macroglobulinemia 2Recurrence 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Lymphoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × ublituximab × Clear all
NCT03804996 2024-04-08

Study of TG-1801 in Subjects With B-Cell Lymphoma

TG Therapeutics, Inc.

Phase 1 Completed
50 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT03778073 2022-08-22

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

TG Therapeutics, Inc.

Phase 1 Terminated
18 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡